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Homocysteine, Folate, and Vitamins B6 and B12 Blood Levels in Relation to
Cognitive Performance: The Maine-Syracuse Study
MERRILL F. ELIAS, PHD, MPH, MICHAEL A. ROBBINS, PHD, MARC M. BUDGE, MBBS, BMEDSC,
PENELOPE K. ELIAS, PHD, SUZANNE L. BRENNAN, CAROLE JOHNSTON, BSC, ZSUZSANNA NAGY, MD, DPHIL,
AND CHRISTOPHER J. BATES, DPHIL
Objective: Our objective was to examine associations among plasma homocysteine concentrations (tHcy), the tHcy-cofactors
(folate, vitamins B6 and B12), and multiple domains of cognitive performance, with statistical adjustment for possible confounds,
including cardiovascular disease risk factors (CVD-RF) and cardiovascular disease (CVD). Methods: Subjects were 812 partici-
pants (58% women) of the Maine-Syracuse study who were free of dementia and stroke. Employing a cross-sectional design and
multiple regression analyses, fasting concentrations of tHcy and its vitamin cofactors (folate, B6, and B12) were related to multiple
domains of cognitive performance. Results: With adjustment for age, education, gender, ethnicity, and the vitamins, tHcy was
inversely associated with visual-spatial organization, working memory, scanning-tracking, and abstract reasoning. The same results
were found with adjustment for age, education, gender, ethnicity, CVD-RF, and CVD. Vitamin cofactors were positively related
to cognitive performance, but with adjustment for CVD-RF and CVD, only vitamin B6 was related to multiple cognitive domains.
Conclusions: The inverse association of tHcy with multiple domains of cognitive functioning is not necessarily dependent on
vitamin levels, vitamin deficiency, prevalent CVD risk factors, and manifest CVD. Serum folate, serum B12, and plasma B6 vitamin
concentrations are positively associated with cognitive performance. Investigation of other possible mechanisms (e.g., tHcy
neurotoxicity) mediating tHcy associations with cognitive performance is important, as are clinical trials examining the efficacy of
folate, vitamin B6, and vitamin B12 for maintenance of cognitive functioning. Key words: cardiovascular risk factors, cognitive
performance, folate, homocysteine, vitamin B6, vitamin B12.
CVD-RF  cardiovascular disease risk factor; CVD  cardiovas-
cular disease; tHcy  total plasma homocysteine; MSLS  Maine-
Syracuse Longitudinal Study; CES-D  Center for Epidemiological
Studies Depression Scale; SST  serum separator tube; hs-CRP 
high-sensitivity C-reactive protein; HPLC  high-performance liq-
uid chromatography; PCR polymerase chain reaction; BP blood
pressure; BMI  body mass index; ApoE  apolipoprotein E;
nl-tHcy  natural log total homocysteine; nl-folate  natural log
folate; nl-B6  natural log vitamin B6.
INTRODUCTION
Homocysteine (tHcy), an amino acid produced during1-carbon metabolism (1), has emerged as a new risk
factor for cognitive deficit (2–9), cognitive decline (10), and
dementia (11–13). A number of mechanisms have been pro-
posed as mediators of this association. The most direct hy-
pothesis is that higher levels of plasma concentrations of tHcy
have an adverse influence on cognition because they are
neurotoxic (14–17).
Rivaling this explanation are two additional independent
hypotheses. The first relates to the finding that strong associ-
ations between tHcy and vascular disease are observed (18–
21). More specifically, tHcy may be associated with cognitive
performance via its relationship to cardiovascular and cere-
brovascular disease (CVD) (18,19) and cardiovascular risk
factors (CVD-RF) such as blood pressure (BP) (19), cigarette
smoking (20), and serum cholesterol level (19–21). The sec-
ond relates to the fact that the metabolism of tHcy is closely
associated with that of folic acid and the vitamins B6 and B12
(1). Homocysteine is a sensitive marker of vitamin B12 and
folate status (1). Higher folate, vitamin B6, and vitamin B12
concentrations have been positively associated with cognitive
performance in a number of studies (6,9,22–27). Thus, on one
hand, variation in folate, vitamin B6, and vitamin B12 may
explain relations between tHcy and cognitive performance. On
the other hand, CVD-RF or CVD may intervene between tHcy
and cognition. This raises two questions: 1) are associations
between tHcy and cognitive performance attenuated or ne-
gated with adjustment for the vitamin cofactors (folate, vita-
min B6, vitamin B12) either individually or simultaneously; 2)
are associations between tHcy and cognitive performance
attenuated or negated with adjustment for CVD and CVD-RF?
Homocysteine has been related to cognitive performance
previously (2–13,22–25) but, with a few exceptions (9,23), the
approach has been to adjust for vitamins or CVD and
CVD-RF in separate studies. In the MacArthur study (23),
both tHcy data and baseline cognitive data were collected
before folic acid fortification of grain products in the United
States, which has lowered levels of tHcy in the US population
(28). In the Framingham Offspring investigation, tHcy data
were obtained before folic acid food fortification and cogni-
tive performance measures were obtained after fortification
(9). In the present study, tHcy and measures of cognition were
obtained after vitamin fortification.
Our hypotheses were as follows: 1) tHcy will be inversely
related to global performance measures and to multiple cog-
nitive domains; 2) associations between tHcy and cognitive
performance will be attenuated but remain significant when
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adjusted for each of the vitamin cofactors and all three vitamin
cofactors simultaneously; 3) relations between tHcy and cog-
nitive performance will be attenuated but remain statistically
significant with adjustment for CVD and CVD-RF; 4) the vita-
min cofactors, folic acid, vitamin B12, and vitamin B6 will be
positively associated with a majority of cognitive measures, and
these relations will be modestly attenuated but remain statistically
significant with adjustment for CVD and CVD-RF.
METHODS
Participants
The University of Maine and the State University of New York Upstate
Medical University institutional review boards have approved the investiga-
tion. Informed consent for data collection was obtained from all participants.
The sample (Table 1) was provided by the Maine-Syracuse Longitudinal
Study (MSLS) (29,30). This community-based study, initiated in 1975, in-
volved a time-lagged sample of men and women (five cohorts defined by time
of entry) who participated between 1975 and 2000 in studies designed to
characterize the effects of hypertension and hypertension-related diseases on
cognitive functioning (29,30). The MSLS provides data on BP, presence of
CVD-RF, history of CVD, stroke, prescription drugs, and cognitive function-
ing, based on medical examination, an in-depth diagnostic interview, and
hospital and physician records. At the sixth study examination (April 2001 to
January 2005), additional data on tHcy, plasma concentrations of vitamin B6,
and serum concentrations of folate and vitamin B12 were obtained.
Of the 854 participants at the sixth examination, participants were ex-
cluded for the following reasons: 1) dementia (n  8); 2) confirmed clinical
stroke history (n  29); 3) active dialysis treatment (n  5). The clinical
diagnosis of dementia was determined by the investigators using the National
Institute of Neurological and Communicative Diseases and Stroke/Alzhei-
mer’s Disease and Related Disorders (NINCDS-ADRDA) criteria (31). His-
tory of stroke was based on self-report and record review (with permission),
confirmed by hospitalization, treatment for stroke, or both. After exclusions,
the sample consisted of 812 (58% women) community-dwelling adults, rang-
ing in age from 26 to 98 years. Compared with the sample from an MSLS
study (n  1679) of baseline cognitive performance (30), the current sample
was older (mean difference  12.0 years), exhibited lower systolic BP (mean
difference  6.2 mm Hg) and diastolic BP (mean difference  10.0 mm Hg),
and had a higher prevalence of CVD (15.8% versus 3.2%).
Procedure
Participants completed psychological inventories, including the Center for
Epidemiological Studies Depression Scale (CES-D), just before attending the
study center. They were admitted to the study center following a fast from
midnight. A blood sample was drawn by a licensed phlebotomist, and a light
breakfast, including decaffeinated coffee or tea, was served. Breakfast was
followed by a physical examination, including a detailed medical history. This
was followed by administration of the test battery by a psychological examiner.
Assays
Fasting blood samples were collected in standard ethylenediaminetet-
raacetic acid tubes for plasma tHcy and plasma B6 determinations and in
serum separator tube (SST) (gel and clot activator) tubes for serum determi-
nations. All blood samples were immediately sent on ice to Centrex Clinical
Laboratories, Syracuse, NY, for immediate processing and determination of
serum folate, serum vitamin B12, lipid profile, triglycerides, glucose, and
creatinine. Serum folate and serum vitamin B12 concentrations were deter-
mined using a paramagnetic particle, chemiluminescent immunoassay on a
Beckman Coulter Immunoassay System. Serum creatinine was determined
using a 2-point rate test type on a Johnson and Johnson Vitros Instrument.
Coefficients of variation for these procedures were less than 5.0%.
Plasma samples used for determination of tHcy, vitamin B6 (plasma
pyridoxal 5-phosphate), and high-sensitivity C-reactive protein (hs-CRP)
were stored at40°C. Batches of 100 to 150 samples were shipped on dry ice
to Oxford, UK, and Cambridge, UK, for analysis. Plasma tHcy concentrations
were determined at the University of Oxford (Pharmacology Department)
using a fluorescence polarization immunoassay (Axis-Shield, Dundee, UK)
on an Abbott IMx auto-analyzer (Abbott Laboratories, Chicago, IL,USA)
(32). The coefficient of variation for the tHcy assays was less than 3.5%.
TABLE 1. Demographic and Health Characteristics of the Study Participants (N  812)
Variable Mean SD Variable Percent
tHcy (mol/l) 10.0 3.6 Gender (female) 58.1
Age (yrs) 61.8 12.6 Ethnicity (Caucasian)a 92.9
Education (yr) 14.6 2.7 Obesity (BMI 29.9 kg/m2) 45.3
Folate (ng/ml) 17.0 5.2 CVDb 15.8
Vitamin B6 (PLP,
c nmol/l) 95.6 93.2 Mild renal dysfunctiond 16.3
Vitamin B12 (pg/ml) 526.0 283.7 Depressed mood
e 10.1
Systolic BP (mm Hg) 131.2 21.7 Diabetes mellitusf 12.4
Diastolic BP (mm Hg) 70.7 10.0 ApoE 4 genotype 26.8
Alcohol (oz/week) 1.5 2.8 Folate deficiencyg 0.0
Cigarettes/week 9.0 36.8 Vitamin B12 deficiency
h 3.8
Total cholesterol (mg/dl) 203.9 39.5 Vitamin B6 deficiency
i 13.7
Body mass index (BMI, kg/m2) 29.4 6.1
Coffee (cups/day) 1.8 1.9
Creatinine clearance j (ml/min) 91.8 34.6
a Non-Hispanic Caucasian.
b CVD includes the following diagnostic categories: (1) myocardial infarction, n  35 (4.3%); (2) coronary artery disease, n  66 (8.1%); (3) congestive heart
failure, n  20 (2.5%); (4) angina pectoris, n  49 (6.0%); (5) transient ischemic attack, n  30 (3.7%).
c Pyridoxal 5-phosphate.
d Estimated creatinine clearance 60 ml/min.
e CES-Depression scores 16.
f Treatment with antidiabetic drugs or fasting glucose levels of 126 mg/dl or greater.
g Folate deficiency defined as value 3 ng/ml.
h Vitamin B12 deficiency defined as value 200 pg/ml.
i Vitamin B6 PLP deficiency defined as value 30 nmol/l.
j Estimated using the Cockcroft-Gault Formula (Cockcroft and Gault, 1976 (37)).
M. F. ELIAS et al.
548 Psychosomatic Medicine 68:547–554 (2006)
Vitamin B6 (plasma pyridoxal 5-phosphate) and hs-CRP concentrations were
determined at the Medical Research Council Human Nutrition Research Labo-
ratory, Cambridge, UK. For vitamin B6, a Waters Empower 2010-controlled
high-performance liquid chromatography (HPLC) system (Watford, UK) and a
Waters 474 Scanning Florescence Detector was used. The HPLC system is a
Waters 2695 Alliance separation module (Waters Symmetry Shield RP8, 5 m,
4.6  250 mm). Assay control is via a dual-level lyophilized standard from
ChromSystems diagnostics by HPLC. Coefficients of variation for the plasma
pyridoxal 5-phosphate assays were 3.75% or less (33). Plasma hs-CRP was
determined by a latex particle enhanced turbidimetric immunoassay technique
(34). The Flex reagent cartridge was used on the Dimension clinical chemistry
system.
Standard apolipoprotein E (ApoE) genotyping, using polymerase chain
reaction (PCR) and restriction enzyme digest with Hhal (35) was done at the
Neuroscience Division, Medical School, University of Birmingham, UK.
DNA was extracted from buffy coats using a chemical purification method
(DNA isolation kit, Roche). Extracted DNA was used in the PCR, using
ABgene Mastermix containing 1.5 mmol/l MgCl2, 10% dimethyl sulfoxide
(DMSO), and 1 M of primers F4 and F6 each (Metabion) for the amplifi-
cation of exon 4. Amplified products were digested with Hha1 (Roche)
following the protocol from the supplier. Digested products were separated on
agarose gel containing 0.83% multipurpose agarose and 2.67% Metaphore
agarose and 1:10000 Gelstar (Cambrex). Results were viewed under ultravi-
olet light.
Neuropsychological Battery
The test battery is described in Table 2. It was designed to measure a wide
range of cognitive abilities (36) and has been employed in studies relating
hypertension and other risk factors to cognitive performance (e.g., 29,30). The
factor loadings shown are discussed in the factor analytic section below.
Predictors and Covariates
The independent variables were tHcy (mol/l), serum folate (ng/ml),
plasma vitamin B6 (nmol/l), and serum vitamin B12 (pg/ml). Additional
covariables were age (years), gender, education (years), ethnicity, diabetes
mellitus, systolic BP (mm Hg), presence of CVD, self-reported number of
cigarettes smoked per day, total cholesterol (mg/dl), self-reported alcohol
consumption (ounces per week), body mass index (kg/m2, BMI), self-reported
coffee consumption (number of 8-oz cups per day), presence of mild renal
dysfunction, ApoE genotype, depressed mood, and hs-CRP. Diabetes mellitus
was defined as follows: treatment with insulin, oral antidiabetic agents, or
fasting glucose level of 126 mg/dl or above. Mild renal dysfunction was
defined as an estimated creatinine clearance using the Cockcroft-Gault for-
mula (37) of less than 60 ml/min (38). ApoE genotype was defined as one or
two e4 alleles versus no e4 alleles. Using the Framingham Study criteria (39),
CVD was defined by the presence of any of the following: myocardial
infarction (4.3%), coronary artery disease (8.1%), congestive heart failure
(2.5%), angina pectoris (6.0%), transient ischemic attack (3.7%). We em-
ployed CES-D as a categorical variable (16 versus 16 points) for two
reasons: 1) there was a significant skew in CES-D scores; 2) we wished to use
a widely employed clinically relevant index of depressed mood (CES-D16)
(40). The average number of prior exposures to the tests in each test com-
posite (see factor analysis below) was determined and used as a covariate. All
covariates used in our models were identified as important based on the
literature on tHcy, and all were related significantly to tHcy or cognitive
performance in the present study.
Statistical Analysis Plan
Distributions of tHcy, folate, vitamin B6, and vitamin B12 concentrations
were all skewed, and thus were subjected to a natural log transformation to
improve normality. Scores (maximum 5 minutes) on Trail Making A and B
TABLE 2. Descriptions of the Cognitive Tests With Factor Loadings From the Factor Analysis Performed in This Study
Test Composite/Tests Included
in the Composite
Latent Cognitive Variable Tested Factor Loadings
Global composite (z score) Global composite of cognitive performance
Visual-spatial organization
Visual reproductions, immediate recalla Immediate recall, visual memory, and visual-spatial problem solving 0.78
Visual reproductions, delayed recalla Delayed recall, visual memory and visual-spatial problem solving 0.76
Matrix reasoningb Abstract reasoning and pattern recognition 0.75
Block designc Visual-spatial perception, organization and construction 0.68
Object assemblyc Speed of visual-spatial organization 0.66
Hooper visual organization Visual-spatial organization; some demands on executive function 0.63
Scanning and tracking
Trail Making Ad Visual scanning and tracking 0.81
Trail Making Bd Complex visual scanning, tracking and executive function 0.73
Digit symbol substitutionc Psychomotor performance 0.71
Symbol searchb Visual processing speed 0.67
Verbal memory
Logical memory, immediate recalla Immediate memory, verbal 0.91
Logical memory, delayed recalla Delayed memory, verbal 0.91
Hopkins Verbal Learning Test Verbal learning and memory 0.60
Working memory
Digit span forwardc Attention and concentration 0.82
Digit span backwardc Attention, concentration, and working memory 0.80
Letter-number sequenceb Working memory 0.68
Controlled oral word associations Verbal fluency and executive functioning 0.46
Similaritiesa Abstract reasoning NAe
a Origin WMS-R.
b Origin WAIS III.
c Origin WAIS.
d Origin Halstead Reitan NP Test Battery.
e Excluded from the factor analysis.
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were skewed and thus were transformed to natural log values. The natural log
values for Trails A and B and the raw scores on each of the other cognitive
tests were converted to z scores, a linear transformation, in order that regres-
sion coefficients could be expressed in terms of SD units.
Following preliminary analyses, multivariable regression analyses were
performed. In individual analyses, cognitive test scores were regressed on
natural log tHcy (nl-tHcy) using one of the following covariate models in
separate analyses: 1) Basic (age, gender, education, prior test exposures,
ethnicity/race); 2) BasicFolate; 3) Basicvitamin B6; 4) Basicvitamin
B12; 5) BasicFolatevitamin B6vitamin B12; 6) BasicCVD-RFCVD.
The sixth model, BasicCVD-RFCVD, included the following covariates in
addition to the basic covariate set: systolic BP, diabetes mellitus, cigarette smok-
ing, coffee consumption, total cholesterol, mild renal dysfunction, BMI, alcohol
use, ApoE genotype, depressed mood, hs-CRP, and CVD. For the ethnicity/race
variable, participants were classified either as non-Hispanic Caucasian (n 754)
or Other Ethnicity (n  58), i.e., 47 African-Americans, 2 Hispanic Caucasian-
Americans, 3 Asian Americans, and 6 American Indians.
Each of the vitamins also served as an independent variable that, in
separate analyses for each vitamin, was related to the measures of cognitive
performance. Relations between the vitamins and cognition were not adjusted
for tHcy but were adjusted for the Basic and the BasicCVD-RFCVD
covariate models.
Employing the following criteria, cognitive domains, expressed as com-
posite scores, were identified by principal components analysis and orthog-
onal rotation (41): 1) each composite score was constructed from variables
indexing a common cognitive domain; 2) the same individual test score could
not be included in more than one composite; and 3) the domain reflected by
the composite score was theoretically plausible or meaningful. The Similar-
ities Test is highly correlated with general intellectual ability (42) and loaded
on multiple factors. Similarities was thus excluded from the final factor
analysis on an a priori basis but was included as cognitive outcome measure.
RESULTS
Factor Analysis
Principal components and factor analyses yielded four fac-
tors with eigenvalues of 7.31, 1.58, 1.52, and 0.96 extracted.
The remaining eigenvalues were lower than 0.75. Using a
criterion of orthogonally rotated (Varimax) factor pattern
scores greater than 0.45, we found that all cognitive outcome
variables loaded on one of these four factors. Table 2 sum-
marizes the four factors, briefly describes the tests assigned to
each factor, and presents their factor loadings.
In order to allow a straightforward reconstruction of our
composite scores by other investigators using different samples,
we employed the “averaging method” (43) to construct them.
Four composite scores were created by adding the z scores for
each of the individual test scores loading on each factor and then
dividing by the number of z scores. These four composite vari-
ables and the Similarities Test represented the five individual
cognitive domains investigated in this study. In addition, a Global
Composite score was employed as a global measure of cognitive
ability. The Global Composite score was formed by adding the z
scores for all of the variables listed above and dividing by the
number of variables. Once values for the composite scores were
determined, they were again standardized such that the mean for
each composite score was 0.00 with a SD  1.00.
Preliminary Tests
Visual examination of regression and residual (Jacknife)
plots confirmed the appropriateness of the straight-line fit (44)
for each independent variable. Plasma tHcy concentrations are
higher in men than women (18) and tHcy by age interactions
have been reported (2,9). Preliminary tests of interactions,
conducted by injecting tHcy by gender or tHcy by age (years)
interaction terms into the main effects models, were statistically
nonsignificant (p  .20). Inspection indicated a trend for some
regression coefficients relating tHcy to cognition to be larger in
an over-60 age group but also clearly indicated tHcymain effects.
The differences between regression coefficients for the younger
and older groups were nonsignificant (p  .15).
For every model employed, R2 values were statistically
significant (p  .001). The range of R2 values, adjusted for
shrinkage, was R2  0.17 to 0.47 across models and cognitive
performance variables. With adjustment for age, education,
gender, and race/ethnicity, tHcy was significantly and in-
versely correlated (Pearson’s r) with folate (r  0.23, p 
.01), vitamin B6 (r  0.17, p  .01), and vitamin B12 (r 
0.31, p  .01). Pearson’s r correlations among the vitamins
ranged from 0.31 to 0.39.
Plasma THcy
Table 3 displays regression coefficients and standard errors
expressing the magnitude of the associations between nl-tHcy
TABLE 3. Regression Coefficients () and Standard Errors (SE)
Relating Natural Log tHcy to the Cognitive Domain Composite Scores
in SD Units (z Scores)
Cognitive Test
Covariate
Model
(N  812)
 SE
Global Composite Basic 0.3472*** 0.0949
BasicFolate
B6B12
0.2856** 0.1001
BasicCVD-
RFCVD
0.2492* 0.1004
Visual-Spatial Basic 0.3414*** 0.1026
Organization BasicFolate 0.3053** 0.1083
Composite B6B12
BasicCVD-
RFCVD
0.2135* 0.1082
Verbal Memory Basic 0.0616 0.1150
Composite BasicFolate
B6B12
0.0346 0.1220
BasicCVD-
RFCVD
0.0041 0.1234
Working Memory Basic 0.3326** 0.1164
Composite BasicFolate
B6B12
0.3051** 0.1236
BasicCVD-
RFCVD
0.3253** 0.1261
Scanning Tracking Basic 0.2876** 0.0960
Composite BasicFolate
B6B12
0.2683** 0.1014
BasicCVD-
RFCVD
0.2179* 0.1024
Similarities (Abstract Basic 0.3653*** 0.1111
Reasoning) BasicFolate
B6B12
0.2517* 0.1173
BasicCVD-
RFCVD
0.2638* 0.1191
* p  .05, ** p  .01, *** p  .001.
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and cognitive performance. As noted previously, associations
between tHcy and cognitive performance were adjusted for
folate, vitamin B6, and vitamin B12 in separate models. Re-
sults for these separate models are not shown in Table 3,
because the magnitude of the regression coefficients and the p
values for nl-tHcy were nearly identical to the values shown
for the model in which the vitamin covariates were entered
simultaneously.
Statistically significant inverse associations between nl-
tHcy and cognitive performance were observed for the Global,
Visual-Spatial Organization, Working Memory, and Scan-
ning-Tracking composites and the Similarities test. This was
true with adjustment for all of the covariate models employed.
Regardless of the models employed, there were no statistically
significant associations between nl-tHcy and the Verbal Mem-
ory composite.
An a posteriori analysis was conducted in which the asso-
ciations of nl-tHcy and cognitive performance were adjusted
for all of the covariates simultaneously (BasicFolateB6
B12CVD-RFCVD). The same pattern of results was ob-
served as was observed for the models driven by the study
hypotheses, except that nl-tHcy was no longer related to
Similarities.
Magnitude of Association
Comparisons of the regression coefficients in Table 3 provide
an indication of the relative magnitude of effect of nl-tHcy on
each of the cognitive domains as each cognitive measure is
expressed in z scores. To further illustrate magnitude of the
effects, we compared persons with “high” and “low” tHcy de-
fined in terms of quintiles of the distribution of tHcy. Using the
Global Composite score and the highest quintile of tHcy as an
example, we defined a high tHcy value as a tHcy concentration
11.8 mol/l (lowest value of the fifth quintile) and compared
individuals with high and low tHcy using a categorical regression
analysis. Decrements in cognitive performance associated with
tHcy 11.8 mol/l were as follows: (1) Basic (  0.2578,
SE  0.0688, p  .001); (2) BasicFolateB6B12 ( 
0.2160, SE 0.0710, p .01); and BasicCVD-RFCVD
(  0.1447, SE  0.0715, p  .05). Thus, decrements in
performance in relation to high versus low tHcy ranged from
0.26 to 0.14 SD.
Vitamins
The linear regression coefficients in Table 4 express the
associations between natural log folate (nl-folate) concentra-
tions and cognitive performance. For the Basic model, nl-
folate was positively and significantly related to the Global,
Working Memory, and Scanning-Tracking composites and
Similarities. With adjustment for the BasicCVD-RFCVD
covariate set, nl-folate was significantly and positively related
only to the Global and Scanning-Tracking composite scores.
Linear regression coefficients in Table 5 express the asso-
ciations between natural log B6 (nl-B6) and cognitive perfor-
mance. Natural log B6 was positively related to every cognitive
outcome variable for the Basic covariate model. It was also
positively and significantly related to every cognitive domain
for the BasicCVD-RFCVD model with one exception,
i.e., the Verbal Memory composite (p  .05).
Natural log vitamin B12 was not significantly associated
with the Global Composite score, and was related only to
Similarities in both the Basic model (  0.2175, p  .001),
and the BasicCVD-RFCVD model ( 0.1920, p .01).
TABLE 4. Regression Coefficients () and Standard Errors (SE)
Showing the Association Between Natural Log Serum Folate
Concentrations and Test Scores in SD Units (z Scores)
Cognitive Test Model
(N  812)
 SE
Global Composite Basic 0.2236** 0.0815
BasicCVD-
RFCVD
0.1763* 0.0815
Visual-Spatial Basic 0.1256 0.0872
Organization BasicCVD- 0.0926 0.0870
Composite RFCVD
Verbal Memory Basic 0.1450 0.0976
Composite BasicCVD-
RFCVD
0.1343 0.0996
Working Memory Basic 0.2240* 0.1000
Composite BasicCVD-
RFCVD
0.1751 0.1025
Scanning Tracking Basic 0.2151** 0.0814
Composite BasicCVD-
RFCVD
0.1733* 0.0824
Similarities (Abstract Basic 0.2382* 0.0956
Reasoning) BasicCVD-
RFCVD
0.1818*** 0.0968
* p  .05; ** p  .01, ˆ p  .07.
TABLE 5. Regression Coefficients () and Standard Errors (SE)
Showing the Association Between Natural Log Plasma Vitamin B6
(PLP) Concentrations and Test Scores in SD Units (z scores)
Cognitive Test Model
(N  812)
 SE
Global Composite Basic 0.1667*** 0.0339
BasicCVD-
RFCVD
0.1361*** 0.0346
Visual-Spatial Basic 0.1455*** 0.0364
Organization BasicCVD- 0.1200** 0.0370
Composite RFCVD
Verbal Memory Basic 0.0927* 0.0408
Composite BasicCVD-
RFCVD
0.0743 0.0423
Working Memory Basic 0.1382*** 0.0418
Composite BasicCVD-
RFCVD
0.1134** 0.0437
Scanning Tracking Basic 0.1235*** 0.0341
Composite BasicCVD-
RFCVD
0.1010** 0.0351
Similarities (Abstract Basic 0.1837*** 0.0398
Reasoning) BasicCVD-
RFCVD
0.1474*** 0.0411
* p  .05; ** p  .01; *** p  .001.
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None of our participants had serum concentrations of folate
suggestive of deficiency. Relatively few persons exhibited
blood concentrations of vitamin B6 (13.8%) and vitamin B12
(3.7%) suggestive of deficiency (see Table 1 for definitions).
Consequently, to illustrate the practical importance of the
associations of folate and B6 with cognition, we compared
persons with values of folate and B6 concentrations above the
lowest quintile (folate 12 ng/ml; and B6 35 nmol/l) with
persons for whom folate and B6 concentrations were in the
lowest quintile. Folate and B6 blood concentrations above the
lowest quintile were positively associated with cognitive per-
formance. Increments in Global composite scores for persons
above the lowest quintile in B6 were 0.31 SD (  0.3072,
p  .001) for the Basic model and 0.24 SD (  0.2391, p 
.001) for the BasicCVD-RFCVD model. Increments in
Global composite scores for persons above the lowest quintile
in folate were 0.16 SD (  0.1619, p  .05) with adjustment
for the Basic model and 0.12 SD ( 0.1236, p .08) for the
BasicCVD-RFCVD covariate model.
Additional Analyses
Three additional sets of separate analyses were performed.
First, where vitamin deficiency was observed (B6 and B12) we
replaced the B6 and B12 concentration values with vitamin
deficiency (yes/no) variables. Relations between tHcy and
cognition remained significant and were stronger. Second,
women (n  85) treated with hormone replacement therapy, a
correlate of tHcy, were excluded from the sample. The pattern
of significant results was the same. Third, a class variable
(yes/no) for vitamin supplementation was added to the
BasicCVD-RFCVD model. We considered vitamin sup-
plementation as a healthy lifestyle variable, possibly affecting
the relations seen between nl-folate, nl-B6 and cognition.
Essentially, results for the vitamins were the same when
vitamin supplementation was added to the covariate models.
DISCUSSION
Plasma tHcy
We found inverse associations between tHcy and cognitive
performance for the Global composite score and four out of
five cognitive domains examined. While attenuated modestly
in magnitude, these associations remained statistically signif-
icant (p values .05) despite adjustment for the vitamin
cofactors. The modest reduction in associations between tHcy
and cognitive performance with control for the vitamins may
be related to the fact that the prevalence of vitamin deficiency
was relatively low in our study. Nevertheless, our study and
previous studies (9–11) indicate that associations between
tHcy and cognitive performance are not necessarily attribut-
able to vitamin status or deficiency.
While relations between tHcy and cognitive performance
were attenuated by adjustment for the BasicCVD-RFCVD
covariate model, they remained statistically significant. This
finding is consistent with a recent study using a large population-
based sample, i.e., the Framingham Offspring Study, where in-
verse relations between tHcy and multiple cognitive test scores
were maintained when adjusted for a composite index of risk for
future stroke and additional CVD risk factors (9).
It appears, then, that tHcy is not simply a proxy for CVD
or CVD-RF in the absence of clinical manifestation of CVD.
Other mechanisms explaining the association between tHcy
and cognition must be considered. Although untested in the
present study, neurotoxicity leading to cell death (14,15) and
excitotoxicity (15,16) leading to degradation in neurotrans-
mission (16,19) are possible mechanisms. These adverse
events appear to operate at very high levels of tHcy, and thus
it can be argued that they cannot account for linear relations
between tHcy and cognitive performance over less extreme
tHcy concentrations (23).
It is also possible that subclinical vascular disease serves as
one of a number of mechanisms linking tHcy and cognitive
performance. Plasma tHcy may influence cognitive perfor-
mance by way of silent infarcts, white matter lesions, and
brain atrophy (45–47).
Similar results were found in the Framingham Offspring
tHcy study (9) and our study. However, our study differed in
several important respects. We employed a more comprehen-
sive test battery and thus were able to associate tHcy with very
specific domains of cognitive ability. Our sample included mi-
nority subjects but excluded individuals on kidney dialysis treat-
ment. We included C-reactive protein and depressed mood in the
CVD-RF covariate set.
In the Framingham Offspring Study, tHcy was assessed
before folic acid fortification of grain products in the United
States and cognitive performance was measured after fortifi-
cation (9). In the MacArthur study (23), tHcy and cognitive
performance were measured before folic acid fortification. In
our study, tHcy and cognitive performance were assessed after
fortification. Clearly, the shift of the distribution of tHcy
values to lower levels after fortification (28) does not negate
relations between tHcy and cognitive performance.
Unlike the Framingham tHcy study (9), we found signifi-
cant relations between tHcy and cognitive performance for
persons less than 60 years of age. We have no explanation for
this finding, given the various differences in design features
summarized above. It seems possible, though speculative, that
our more comprehensive battery, including composites of test
scores, resulted in more sensitivity to tHcy-associated cogni-
tive deficits in the younger adults.
The Vitamins
Our hypothesis that the vitamins would be positively re-
lated to multiple cognitive domains when adjusted for CVD
risk factors and CVD was confirmed only for vitamin B6. This
is important because only a few studies have shown positive
relations between vitamin B6 and cognition (6,23,26). Consis-
tent with this finding, there is evidence that B6 supplementa-
tion may improve cognitive performance in elderly men (48).
Vitamin B12 was related only to the Similarities test (ab-
stract reasoning), and folate was related only to the Scanning
and Tracking composite (including measures of executive
performance). The fact that vitamin B6 was related to multiple
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cognitive domains and the other vitamins were related to a
single cognitive domain may relate to the fact that the prev-
alence of vitamin deficiency in our study was modestly higher
for vitamin B6 than for the other vitamins.
It has been hypothesized that folate and vitamins B6 and
B12 are related to cognitive performance because tHcy metab-
olism requires these vitamins (22). Consequently, disruption
of methylation pathways may lead to cognitive impairment via
the accumulation of S-adenosylhomocysteine, a strong inhib-
itor of the majority of methyl tranferase enzymes (23).
In the MacArthur study (23), when sex and age were
adjusted, lower levels of folate and B6 were associated with an
increasing risk of cognitive decline, whereas B12 was not.
Folate alone was related to cognitive performance after ad-
justment for various covariate models including some CVD
variables. In our study, folate exhibited a positive linear as-
sociation with the Global and Scanning/Tracking composite
scores despite adjustment for the CVD covariate set. Clearly,
however, B6 emerged as the more consistent predictor of
cognitive performance across cognitive domains. Regardless
of the covariance model employed, B6 was significantly as-
sociated with every cognitive domain but Verbal Memory.
Whether these relationships are causal and whether B6 sup-
plementation can improve cognitive performance can only be
revealed by longitudinal studies and the results of ongoing
clinical trials.
Limitations of our study include: 1) the cross-sectional
design; 2) the high average education level of our participants;
3) absence of measures of subclinical vascular disease; and 4)
our CVD categories were based on self-report, a medical
diagnostic interview, treatment history, and record confirma-
tion. Consequently, presence of CVD may have been under-
estimated.
Strengths of the study include: 1) the availability of objec-
tive clinical data on multiple CVD risk factors; 2) the mea-
surement of folate, the PLP form of vitamin B6, and vitamin
B12, as well as tHcy; and 3) an extensive battery of tests
permitting a factor analytic approach to the identification of
cognitive domains.
Conclusions and Epidemiological Implications
Our findings indicate that tHcy is inversely associated with
multiple domains of cognitive functioning and that these as-
sociations are not due simply to vitamin deficit, vitamin status,
or the presence of manifest CVD risk factors or history of
CVD events. Vitamin B6 was positively related to the same
cognitive domains as tHcy when adjusted for the CVD and
risk factor covariates and vitamin supplementation. The mag-
nitude of the effect of tHcy on cognitive performance does not
rise to the level of serious clinical deficit. However, deficits of
this magnitude are of considerable importance in large popu-
lations. In subsets of individuals, deficits of this magnitude
herald more catastrophic deficits later in life (49). More stud-
ies are needed in order understand the mechanisms linking
tHcy to cognitive performance. Only ongoing and future clin-
ical trials can resolve whether these associations are causal
and whether targeted folate and vitamin B6 supplementation
protects against deficits in cognitive performance.
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